Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates
Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility. To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-d...
Uloženo v:
| Vydáno v: | European urology Ročník 77; číslo 1; s. 38 - 52 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
Elsevier B.V
01.01.2020
|
| Témata: | |
| ISSN: | 0302-2838, 1873-7560, 1873-7560 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility.
To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data.
We present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries.
The highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries).
As evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality).
We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased.
We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates mostly stabilized or decreased. These trends may reflect declines in prostate-specific antigen testing (incidence) and improvements in treatment (mortality). |
|---|---|
| AbstractList | Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility.
To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data.
We present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries.
The highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries).
As evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality).
We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased. Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility.CONTEXTPrevious studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility.To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data.OBJECTIVETo assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data.We present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries.EVIDENCE ACQUISITIONWe present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries.The highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries).EVIDENCE SYNTHESISThe highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries).As evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality).CONCLUSIONSAs evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality).We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased.PATIENT SUMMARYWe examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased. Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility. To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data. We present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries. The highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries). As evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality). We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased. We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates mostly stabilized or decreased. These trends may reflect declines in prostate-specific antigen testing (incidence) and improvements in treatment (mortality). |
| Author | Jemal, Ahmedin Bray, Freddie Efstathiou, Jason A. Culp, MaryBeth B. Soerjomataram, Isabelle |
| Author_xml | – sequence: 1 givenname: MaryBeth B. orcidid: 0000-0002-7851-0233 surname: Culp fullname: Culp, MaryBeth B. email: MaryBeth.Culp@cancer.org organization: Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA – sequence: 2 givenname: Isabelle surname: Soerjomataram fullname: Soerjomataram, Isabelle organization: Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France – sequence: 3 givenname: Jason A. orcidid: 0000-0003-0996-0350 surname: Efstathiou fullname: Efstathiou, Jason A. organization: Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA – sequence: 4 givenname: Freddie surname: Bray fullname: Bray, Freddie organization: Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France – sequence: 5 givenname: Ahmedin surname: Jemal fullname: Jemal, Ahmedin organization: Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31493960$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkMFqGzEQhkVJaRy3b1CKjr3sdrRaraVSCsU0TiAhIbRnodXOglxZm0ragt--Mk5yyMUnDej7f2a-C3IWpoCEfGRQM2Ddl22Nc5zjVDfAVA2yBhBvyILJFa9WooMzsgAOTdVILs_JRUpbAOBC8XfknLNWcdXBgmwe0GLIdOOn3nh6b3LGGBJ1gd7HKWWTka5NsBjpdbBuwDJSEwZ6O8VsvMt7-lCY9J68HY1P-OHpXZLflz9_ra-qm7vN9frHTWVbyXIlcETVDUrA2LRKWCGt6ss25ReafkCubMs6IbjkTV-GfkQB0A7MCAFcDXxJPh97H-P0d8aU9c4li96bgNOcdNPIlWAtL_SSfHpC536Hg36MbmfiXj8fX4D2CNhyaYo4viAM9MGx3uqjY31wrEHq4rjEvr6KWVc8uSnkaJw_Ff5-DGOR9M9h1Mm6g9TBRbRZD5M7VfDtVYH1Ljhr_B_cn47_B-bErSg |
| CitedBy_id | crossref_primary_10_1016_j_urolonc_2025_06_018 crossref_primary_10_1002_pros_24625 crossref_primary_10_1136_jcp_2025_210299 crossref_primary_10_1038_s41598_024_82958_8 crossref_primary_10_1007_s00432_023_05293_x crossref_primary_10_1016_j_eururo_2025_05_038 crossref_primary_10_1016_j_urolonc_2020_12_001 crossref_primary_10_1016_j_urology_2023_05_002 crossref_primary_10_1038_s41598_021_01140_6 crossref_primary_10_4103_jrcr_jrcr_20_25 crossref_primary_10_3390_curroncol32080426 crossref_primary_10_1016_j_cpet_2023_06_001 crossref_primary_10_1016_j_contre_2025_100079 crossref_primary_10_1016_j_microc_2025_114461 crossref_primary_10_1038_s41467_023_39865_9 crossref_primary_10_1038_s41598_025_07361_3 crossref_primary_10_1186_s12885_024_13147_z crossref_primary_10_1002_pros_24857 crossref_primary_10_1016_j_canlet_2022_215829 crossref_primary_10_1002_pros_24859 crossref_primary_10_3390_cancers14184476 crossref_primary_10_1007_s10103_025_04357_3 crossref_primary_10_3390_diagnostics12092101 crossref_primary_10_5194_ms_13_399_2022 crossref_primary_10_1186_s12967_022_03575_5 crossref_primary_10_1186_s13063_020_04515_8 crossref_primary_10_1002_cam4_7320 crossref_primary_10_1007_s11255_025_04465_7 crossref_primary_10_3390_ijms24097746 crossref_primary_10_1016_j_clgc_2023_02_003 crossref_primary_10_1002_pros_24646 crossref_primary_10_1002_pros_24647 crossref_primary_10_1007_s00259_022_05927_1 crossref_primary_10_3390_medicina58121820 crossref_primary_10_1021_acs_jmedchem_5c00741 crossref_primary_10_1016_j_canep_2025_102931 crossref_primary_10_1016_j_colsurfa_2025_136269 crossref_primary_10_1007_s00261_024_04560_w crossref_primary_10_1186_s12962_023_00493_1 crossref_primary_10_1200_GO_20_00571 crossref_primary_10_1016_j_semradonc_2021_09_003 crossref_primary_10_36303_AUJ_0188 crossref_primary_10_1080_14737159_2021_1996227 crossref_primary_10_1016_j_coemr_2020_02_005 crossref_primary_10_1186_s41181_021_00150_z crossref_primary_10_3389_fpsyg_2024_1392167 crossref_primary_10_4155_bio_2020_0242 crossref_primary_10_1016_j_canlet_2024_217310 crossref_primary_10_1016_j_rxeng_2022_12_005 crossref_primary_10_1007_s12672_024_01130_w crossref_primary_10_1007_s11701_022_01383_z crossref_primary_10_5507_bp_2025_003 crossref_primary_10_3389_fimmu_2024_1507355 crossref_primary_10_3390_cancers15143549 crossref_primary_10_1371_journal_pone_0331613 crossref_primary_10_1002_pros_24821 crossref_primary_10_1016_j_acuroe_2022_10_003 crossref_primary_10_3390_cancers17061031 crossref_primary_10_1007_s40273_024_01466_9 crossref_primary_10_3389_fnut_2024_1390379 crossref_primary_10_3390_medicina60091452 crossref_primary_10_1002_fsn3_70580 crossref_primary_10_1007_s00411_022_00991_5 crossref_primary_10_3389_fphar_2025_1478331 crossref_primary_10_1080_13813455_2024_2430488 crossref_primary_10_1007_s10103_023_03848_5 crossref_primary_10_1515_med_2024_1136 crossref_primary_10_1136_jitc_2022_006020 crossref_primary_10_1016_j_euros_2020_12_004 crossref_primary_10_1186_s12935_024_03231_6 crossref_primary_10_1007_s11255_022_03293_3 crossref_primary_10_1016_j_bcp_2025_116749 crossref_primary_10_1016_j_ebiom_2021_103432 crossref_primary_10_3390_s21124099 crossref_primary_10_5694_mja2_51073 crossref_primary_10_3390_nu16060800 crossref_primary_10_1007_s00261_025_05019_2 crossref_primary_10_7759_cureus_71158 crossref_primary_10_9778_cmajo_20220069 crossref_primary_10_1002_cam4_70528 crossref_primary_10_1007_s11654_019_00192_5 crossref_primary_10_1007_s10147_020_01798_4 crossref_primary_10_1007_s12672_023_00671_w crossref_primary_10_3390_biom11060794 crossref_primary_10_1016_j_molliq_2020_114937 crossref_primary_10_3390_ijms22094394 crossref_primary_10_1007_s12668_024_01459_0 crossref_primary_10_3389_fsurg_2023_1132303 crossref_primary_10_3389_fcell_2020_00827 crossref_primary_10_3389_fonc_2022_932637 crossref_primary_10_3390_ijms22020754 crossref_primary_10_1016_j_euo_2024_04_011 crossref_primary_10_2147_IJN_S304515 crossref_primary_10_1002_cncr_34337 crossref_primary_10_1080_13685538_2020_1766013 crossref_primary_10_1186_s40644_024_00693_9 crossref_primary_10_3390_cancers17111831 crossref_primary_10_1007_s00520_023_08078_7 crossref_primary_10_3390_cancers17152573 crossref_primary_10_1186_s12964_022_00979_0 crossref_primary_10_1080_14756366_2020_1753721 crossref_primary_10_3389_fphar_2023_1160440 crossref_primary_10_3389_fonc_2020_598801 crossref_primary_10_3892_mco_2025_2887 crossref_primary_10_1038_s41391_021_00451_z crossref_primary_10_1016_j_euo_2024_04_016 crossref_primary_10_1038_s41585_021_00442_8 crossref_primary_10_1016_j_remnie_2024_500045 crossref_primary_10_1016_j_clinbiochem_2023_04_011 crossref_primary_10_1111_ans_17263 crossref_primary_10_1155_ijog_6681711 crossref_primary_10_1016_j_remnie_2024_500047 crossref_primary_10_3390_pharmaceutics15041214 crossref_primary_10_1186_s12889_022_14207_4 crossref_primary_10_7759_cureus_63506 crossref_primary_10_1007_s00259_025_07190_6 crossref_primary_10_1155_2022_7827821 crossref_primary_10_1200_GO_20_00505 crossref_primary_10_1007_s10147_024_02660_7 crossref_primary_10_1038_s41391_023_00690_2 crossref_primary_10_3390_app142310947 crossref_primary_10_1016_j_urolonc_2020_06_019 crossref_primary_10_1016_j_euros_2025_05_013 crossref_primary_10_1111_ans_70270 crossref_primary_10_1093_jjco_hyaa161 crossref_primary_10_3390_vaccines10081370 crossref_primary_10_1136_bcr_2022_249816 crossref_primary_10_1002_pros_24471 crossref_primary_10_1007_s11845_023_03448_w crossref_primary_10_1371_journal_pone_0290110 crossref_primary_10_1016_j_lana_2022_100294 crossref_primary_10_7759_cureus_27646 crossref_primary_10_1080_10255842_2024_2427118 crossref_primary_10_1016_j_cpt_2024_03_004 crossref_primary_10_3390_cancers15041166 crossref_primary_10_1186_s13690_025_01503_9 crossref_primary_10_1002_cam4_70563 crossref_primary_10_1007_s00432_023_04910_z crossref_primary_10_1016_j_repbio_2022_100674 crossref_primary_10_3389_fonc_2024_1438297 crossref_primary_10_1186_s12894_021_00810_x crossref_primary_10_3390_cancers17010020 crossref_primary_10_3390_medicina60091482 crossref_primary_10_1016_j_urology_2023_04_021 crossref_primary_10_2478_raon_2020_0008 crossref_primary_10_1186_s12935_021_02126_0 crossref_primary_10_1002_1878_0261_70069 crossref_primary_10_1016_j_acuro_2025_501838 crossref_primary_10_3390_medicina59091589 crossref_primary_10_1007_s00604_022_05458_4 crossref_primary_10_1016_j_eururo_2020_05_018 crossref_primary_10_1016_j_urolonc_2020_10_017 crossref_primary_10_1007_s12094_024_03619_w crossref_primary_10_1097_NCC_0000000000001282 crossref_primary_10_1186_s13244_021_00990_y crossref_primary_10_1067_j_cpradiol_2025_08_002 crossref_primary_10_1016_j_euo_2024_11_010 crossref_primary_10_3390_cancers14071702 crossref_primary_10_62347_WRBD9281 crossref_primary_10_1016_j_ucl_2024_07_004 crossref_primary_10_3390_cancers17010043 crossref_primary_10_1371_journal_pone_0276050 crossref_primary_10_1371_journal_pone_0299398 crossref_primary_10_1016_j_euo_2024_11_009 crossref_primary_10_2147_IJGM_S419039 crossref_primary_10_1002_cam4_6826 crossref_primary_10_3390_ijms25094762 crossref_primary_10_1007_s11356_025_36593_z crossref_primary_10_3390_cancers14163982 crossref_primary_10_1097_MD_0000000000044282 crossref_primary_10_1002_ptr_7494 crossref_primary_10_1038_s41391_024_00789_0 crossref_primary_10_3892_ol_2022_13409 crossref_primary_10_1016_j_jpba_2021_114333 crossref_primary_10_1007_s11548_024_03067_5 crossref_primary_10_3390_life11111251 crossref_primary_10_1007_s12672_025_02672_3 crossref_primary_10_3389_fonc_2025_1481406 crossref_primary_10_1186_s12894_024_01507_7 crossref_primary_10_3389_fonc_2021_810736 crossref_primary_10_1002_cam4_71225 crossref_primary_10_3390_cancers16162797 crossref_primary_10_1002_pros_24673 crossref_primary_10_1016_j_euo_2021_09_006 crossref_primary_10_1097_us9_0000000000000086 crossref_primary_10_1016_j_yao_2021_02_022 crossref_primary_10_1002_pros_24412 crossref_primary_10_1002_cncr_35032 crossref_primary_10_1007_s11042_022_11906_3 crossref_primary_10_1007_s10103_025_04511_x crossref_primary_10_1007_s00432_022_04274_w crossref_primary_10_3390_ijms23116281 crossref_primary_10_1016_j_critrevonc_2025_104653 crossref_primary_10_3390_biomedicines9080986 crossref_primary_10_3390_cancers13184696 crossref_primary_10_3389_fendo_2022_897513 crossref_primary_10_5796_electrochemistry_23_00104 crossref_primary_10_1016_j_ygeno_2021_06_029 crossref_primary_10_3389_fpubh_2022_882586 crossref_primary_10_1038_s41388_022_02255_4 crossref_primary_10_2217_bmm_2022_0409 crossref_primary_10_3390_cancers16162777 crossref_primary_10_1002_pros_24206 crossref_primary_10_1007_s00432_023_05080_8 crossref_primary_10_1016_S1470_2045_23_00646_0 crossref_primary_10_1053_j_semnuclmed_2023_06_005 crossref_primary_10_1007_s11764_025_01882_6 crossref_primary_10_1186_s12894_020_00717_z crossref_primary_10_1097_CU9_0000000000000222 crossref_primary_10_1016_j_bbe_2020_07_011 crossref_primary_10_1159_000542465 crossref_primary_10_3889_oamjms_2022_9388 crossref_primary_10_1186_s13244_023_01544_0 crossref_primary_10_1038_s41391_021_00431_3 crossref_primary_10_1111_apm_13132 crossref_primary_10_1002_cam4_6853 crossref_primary_10_1111_bju_15562 crossref_primary_10_3389_fphar_2021_682337 crossref_primary_10_1007_s00345_020_03553_w crossref_primary_10_2174_1570180820666230502152114 crossref_primary_10_1016_j_canep_2022_102227 crossref_primary_10_3389_fonc_2022_1043688 crossref_primary_10_1016_j_acuro_2022_03_003 crossref_primary_10_1002_pros_24443 crossref_primary_10_1155_2022_9516774 crossref_primary_10_3390_jcm14103318 crossref_primary_10_1038_s41598_024_61866_x crossref_primary_10_1016_j_fjurol_2025_102933 crossref_primary_10_1016_S0140_6736_24_00651_2 crossref_primary_10_1097_JU_0000000000002958 crossref_primary_10_3390_cancers12102993 crossref_primary_10_1002_bco2_17 crossref_primary_10_3390_biology13100762 crossref_primary_10_1007_s12149_024_01942_4 crossref_primary_10_1016_j_clgc_2022_12_009 crossref_primary_10_1016_j_annonc_2020_02_009 crossref_primary_10_3390_cells14131008 crossref_primary_10_1016_j_jvir_2023_09_029 crossref_primary_10_1111_bju_16608 crossref_primary_10_1186_s13020_024_00881_6 crossref_primary_10_1111_pin_13509 crossref_primary_10_1007_s40203_024_00193_5 crossref_primary_10_1186_s12885_023_11018_7 crossref_primary_10_4103_aja202414 crossref_primary_10_1007_s13193_024_01885_2 crossref_primary_10_3390_diagnostics12051271 crossref_primary_10_1016_j_euo_2022_04_009 crossref_primary_10_1016_j_eururo_2019_11_030 crossref_primary_10_3389_fimmu_2025_1564784 crossref_primary_10_1097_COC_0000000000001159 crossref_primary_10_1016_j_ejso_2023_107112 crossref_primary_10_1136_bmjopen_2021_049314 crossref_primary_10_1016_j_cpet_2020_12_001 crossref_primary_10_1097_CEJ_0000000000000762 crossref_primary_10_1016_j_euo_2025_02_010 crossref_primary_10_1109_JSEN_2023_3307176 crossref_primary_10_1016_j_ipha_2023_04_010 crossref_primary_10_3389_fmed_2022_931422 crossref_primary_10_1007_s11307_024_01900_6 crossref_primary_10_1007_s42058_021_00059_1 crossref_primary_10_1590_1413_81232025303_05932023en crossref_primary_10_3389_fsurg_2023_1289765 crossref_primary_10_3390_cancers17091576 crossref_primary_10_3892_etm_2021_10734 crossref_primary_10_1002_ijc_33232 crossref_primary_10_1002_agt2_70008 crossref_primary_10_1002_slct_202500899 crossref_primary_10_1038_s41598_024_80190_y crossref_primary_10_1136_bmjopen_2023_082709 crossref_primary_10_1016_j_clgc_2023_07_003 crossref_primary_10_1089_omi_2023_0065 crossref_primary_10_1016_j_jsxm_2020_11_011 crossref_primary_10_1080_17501911_2025_2535938 crossref_primary_10_1016_j_fpurol_2024_12_001 crossref_primary_10_1016_j_saa_2024_125305 crossref_primary_10_1007_s12094_024_03625_y crossref_primary_10_26442_18151434_2025_1_203054 crossref_primary_10_1007_s00345_025_05707_0 crossref_primary_10_3390_ijms232416028 crossref_primary_10_3390_cancers13143403 crossref_primary_10_5694_mja2_50794 crossref_primary_10_1007_s11255_025_04620_0 crossref_primary_10_1016_j_trac_2024_117978 crossref_primary_10_2217_fon_2020_0557 crossref_primary_10_3390_cancers13092244 crossref_primary_10_1590_1413_81232025303_05932023 crossref_primary_10_3390_antiox10091348 crossref_primary_10_3390_cancers16203506 crossref_primary_10_7759_cureus_59732 crossref_primary_10_3390_cancers14143449 crossref_primary_10_1016_j_eururo_2023_04_021 crossref_primary_10_3389_fmolb_2024_1481375 crossref_primary_10_1007_s12094_025_03884_3 crossref_primary_10_1007_s12094_022_02857_0 crossref_primary_10_1007_s00259_025_07311_1 crossref_primary_10_1080_00958972_2022_2145472 crossref_primary_10_1002_cncr_33815 crossref_primary_10_2340_1651_226X_2025_41334 crossref_primary_10_1007_s12312_020_00810_2 crossref_primary_10_3390_cancers16234010 crossref_primary_10_3390_ijerph22060930 crossref_primary_10_1002_gcc_23218 crossref_primary_10_1016_j_urolonc_2024_09_007 crossref_primary_10_1111_iju_14256 crossref_primary_10_1001_jamanetworkopen_2024_34622 crossref_primary_10_1038_s41391_023_00657_3 crossref_primary_10_21886_2308_6424_2025_13_2_92_102 crossref_primary_10_1016_j_cca_2021_01_018 crossref_primary_10_1186_s13643_023_02282_6 crossref_primary_10_3390_diagnostics10080566 crossref_primary_10_2147_DDDT_S376474 crossref_primary_10_1002_jmri_28428 crossref_primary_10_1016_j_semcancer_2022_02_017 crossref_primary_10_1016_j_urolonc_2025_02_011 crossref_primary_10_1007_s00345_024_05291_9 crossref_primary_10_1038_s41598_025_06548_y crossref_primary_10_3390_pharmaceutics15061617 crossref_primary_10_1007_s00261_020_02903_x crossref_primary_10_1016_j_urolonc_2024_09_004 crossref_primary_10_3390_sym13060974 crossref_primary_10_3389_fonc_2021_771956 crossref_primary_10_1007_s11255_022_03409_9 crossref_primary_10_3390_ijms24065160 crossref_primary_10_1177_20503121251360120 crossref_primary_10_1016_j_prp_2023_154317 crossref_primary_10_1080_17434440_2020_1762487 crossref_primary_10_1038_s41416_023_02271_5 crossref_primary_10_1080_17482631_2024_2436720 crossref_primary_10_4103_jmau_jmau_119_22 crossref_primary_10_32635_2176_9745_RBC_2023v69n2_3763 crossref_primary_10_3390_app12105059 crossref_primary_10_1016_j_euros_2022_05_003 crossref_primary_10_1177_17504589231214388 crossref_primary_10_1177_03915603251322577 crossref_primary_10_1186_s12957_022_02878_7 crossref_primary_10_1016_j_biomaterials_2025_123387 crossref_primary_10_4103_jpo_jpo_16_23 crossref_primary_10_1159_000515784 crossref_primary_10_3389_fonc_2020_00809 crossref_primary_10_3389_fonc_2024_1389250 crossref_primary_10_1055_a_1211_4656 crossref_primary_10_1136_bmjopen_2023_075595 crossref_primary_10_3389_fonc_2022_918830 crossref_primary_10_1002_cncr_33621 crossref_primary_10_1158_1078_0432_CCR_24_3656 crossref_primary_10_1186_s13104_024_06913_6 crossref_primary_10_4274_uob_galenos_2023_2023_3_1 crossref_primary_10_1007_s00345_023_04625_3 crossref_primary_10_7759_cureus_58842 crossref_primary_10_1155_2024_3569968 crossref_primary_10_3390_cancers13164134 crossref_primary_10_1016_j_acuro_2020_06_017 crossref_primary_10_1007_s11033_022_07507_w crossref_primary_10_1007_s12254_025_01060_5 crossref_primary_10_4103_aja202220 crossref_primary_10_3389_fimmu_2021_748741 crossref_primary_10_1007_s11764_022_01256_2 crossref_primary_10_1007_s00296_025_05960_x crossref_primary_10_3390_cancers13123016 crossref_primary_10_3389_fonc_2024_1402217 crossref_primary_10_3390_cancers17132137 crossref_primary_10_3390_ph17111450 crossref_primary_10_1016_j_eururo_2019_09_018 crossref_primary_10_1111_jcmm_18572 crossref_primary_10_1016_j_tox_2022_153212 crossref_primary_10_3390_cancers14174174 crossref_primary_10_1016_j_prp_2021_153507 crossref_primary_10_7759_cureus_45782 crossref_primary_10_1158_2159_8290_CD_20_0751 crossref_primary_10_1016_j_euo_2025_04_008 crossref_primary_10_3390_cancers12051106 crossref_primary_10_1007_s10439_025_03712_3 crossref_primary_10_1186_s12967_022_03398_4 crossref_primary_10_1111_bju_15906 crossref_primary_10_1186_s12880_025_01829_4 crossref_primary_10_3390_jcm12082836 crossref_primary_10_3390_biom10050726 crossref_primary_10_3390_plants12030564 crossref_primary_10_1016_j_hoc_2023_06_007 crossref_primary_10_1016_j_adcanc_2024_100130 crossref_primary_10_1016_j_radphyschem_2024_112407 crossref_primary_10_1007_s00280_021_04379_y crossref_primary_10_1038_s41585_022_00638_6 crossref_primary_10_3389_fgene_2022_976850 crossref_primary_10_1080_15476278_2023_2285836 crossref_primary_10_1016_j_neo_2025_101227 crossref_primary_10_3390_cancers14174189 crossref_primary_10_3390_cancers14246055 crossref_primary_10_1007_s12672_025_02985_3 crossref_primary_10_1016_j_phro_2024_100645 crossref_primary_10_3390_cancers13215574 crossref_primary_10_1177_10732748251320842 crossref_primary_10_1016_j_acuro_2020_05_003 crossref_primary_10_1007_s00432_024_05865_5 crossref_primary_10_3390_healthcare13091049 crossref_primary_10_1016_j_acuroe_2025_501838 crossref_primary_10_1111_ijun_12406 crossref_primary_10_1186_s12885_025_13482_9 crossref_primary_10_1002_bco2_70016 crossref_primary_10_3390_healthcare11202780 crossref_primary_10_1097_CEJ_0000000000000745 crossref_primary_10_1016_j_repbre_2025_03_004 crossref_primary_10_1016_j_euros_2024_06_012 crossref_primary_10_3389_fonc_2021_738078 crossref_primary_10_1242_dmm_052001 crossref_primary_10_1002_bco2_70006 crossref_primary_10_1186_s12894_024_01521_9 crossref_primary_10_1002_bco2_70003 crossref_primary_10_1007_s11604_024_01646_9 crossref_primary_10_3390_cancers14133227 crossref_primary_10_1016_j_exger_2023_112118 crossref_primary_10_1186_s12885_022_09276_y crossref_primary_10_1155_2022_1505087 crossref_primary_10_1177_10547738221100350 crossref_primary_10_3389_fmolb_2022_838654 crossref_primary_10_3389_fonc_2023_1320681 crossref_primary_10_1080_17435889_2025_2481823 crossref_primary_10_3390_nu13020496 crossref_primary_10_3390_biomedicines10112733 crossref_primary_10_1245_s10434_025_17665_3 crossref_primary_10_4274_jarem_galenos_2024_84755 crossref_primary_10_1038_s41598_025_93728_5 crossref_primary_10_1016_j_tranon_2024_102145 crossref_primary_10_1038_s41388_022_02461_0 crossref_primary_10_1088_1742_6596_2562_1_012008 crossref_primary_10_3390_cancers14010040 crossref_primary_10_1016_j_eururo_2024_03_027 crossref_primary_10_1097_GH9_0000000000000397 crossref_primary_10_1093_ije_dyaf062 crossref_primary_10_3390_jcm10112459 crossref_primary_10_1007_s00432_024_05694_6 crossref_primary_10_3892_mmr_2022_12787 crossref_primary_10_1080_14737159_2023_2195553 crossref_primary_10_1016_j_jgo_2023_101559 crossref_primary_10_1200_JCO_23_01157 crossref_primary_10_1007_s00345_023_04644_0 crossref_primary_10_1007_s13577_022_00754_w crossref_primary_10_3389_fpubh_2022_811044 crossref_primary_10_3390_cancers15133438 crossref_primary_10_1002_cam4_5262 crossref_primary_10_1007_s10147_021_02058_9 crossref_primary_10_2174_0929867329666220607162250 crossref_primary_10_1002_bco2_70061 crossref_primary_10_1186_s12885_021_09078_8 crossref_primary_10_1016_j_ejrad_2024_111581 crossref_primary_10_1186_s40164_025_00694_9 crossref_primary_10_1111_ans_17337 crossref_primary_10_1038_s41746_025_01930_6 crossref_primary_10_1136_bmjspcare_2021_002994 crossref_primary_10_1177_1758835920978134 crossref_primary_10_1007_s00270_024_03696_y crossref_primary_10_1016_j_acuroe_2020_06_004 crossref_primary_10_3390_ijms252313090 crossref_primary_10_1111_jcmm_70555 crossref_primary_10_1155_proc_8839773 crossref_primary_10_1002_jmri_29275 crossref_primary_10_1016_j_jpba_2022_115206 crossref_primary_10_1038_s41388_024_03028_x crossref_primary_10_1016_j_eururo_2024_11_013 crossref_primary_10_1161_JAHA_124_040186 crossref_primary_10_1088_1758_5090_acd960 crossref_primary_10_1177_17562872241229250 crossref_primary_10_3389_fonc_2022_918419 crossref_primary_10_1177_03915603241299856 crossref_primary_10_3389_fonc_2022_961086 crossref_primary_10_1186_s40779_021_00354_z crossref_primary_10_1002_ctm2_1028 crossref_primary_10_1002_cam4_5045 crossref_primary_10_1016_j_bcp_2023_116011 crossref_primary_10_3390_antiox13080974 crossref_primary_10_1016_j_bbrc_2022_03_142 crossref_primary_10_3390_diagnostics14151608 crossref_primary_10_3389_fpubh_2023_1267534 crossref_primary_10_1016_j_prnil_2023_07_004 crossref_primary_10_1038_s41391_023_00673_3 crossref_primary_10_3389_fonc_2023_1157949 crossref_primary_10_54803_sauhsd_1589761 crossref_primary_10_1186_s12877_023_04151_2 crossref_primary_10_1002_pros_24706 crossref_primary_10_1016_j_aanat_2023_152115 crossref_primary_10_1038_s41378_021_00243_4 crossref_primary_10_1016_j_radonc_2023_109794 crossref_primary_10_1007_s00261_022_03745_5 crossref_primary_10_3390_cancers16233953 crossref_primary_10_1016_j_urolonc_2024_05_002 crossref_primary_10_1007_s12672_025_02749_z crossref_primary_10_3390_cancers16071303 crossref_primary_10_3389_fonc_2021_711258 crossref_primary_10_1038_s41585_024_00948_x crossref_primary_10_1080_0284186X_2020_1762928 crossref_primary_10_3390_biology10101007 crossref_primary_10_37689_actaape_2020AO02375 crossref_primary_10_1186_s12894_025_01721_x crossref_primary_10_1016_j_amsu_2020_07_015 crossref_primary_10_1016_j_canep_2022_102164 crossref_primary_10_1016_j_seminoncol_2025_152375 crossref_primary_10_1002_cnr2_70206 crossref_primary_10_1016_j_canep_2024_102562 crossref_primary_10_1007_s40615_025_02540_4 crossref_primary_10_4103_aja2022105 crossref_primary_10_1080_13685538_2023_2257300 crossref_primary_10_22328_2079_5343_2025_16_2_95_103 crossref_primary_10_1016_j_canep_2025_102855 crossref_primary_10_4102_sajo_v8i0_275 crossref_primary_10_1007_s40520_024_02861_0 crossref_primary_10_1186_s40001_025_03098_x crossref_primary_10_3348_kjr_2024_0439 crossref_primary_10_3322_caac_70020 crossref_primary_10_3389_fimmu_2023_1205266 crossref_primary_10_3390_cancers14174135 crossref_primary_10_3389_fonc_2023_1130680 crossref_primary_10_1055_a_1348_1634 crossref_primary_10_1016_j_euros_2024_04_001 crossref_primary_10_1002_pros_24713 crossref_primary_10_3390_cancers15194888 crossref_primary_10_1016_j_canlet_2022_215927 crossref_primary_10_1016_j_eururo_2023_09_003 crossref_primary_10_1016_j_omtn_2022_02_010 crossref_primary_10_1007_s10334_022_01011_9 crossref_primary_10_4102_sajo_v8i0_287 crossref_primary_10_1016_j_ejca_2021_07_039 crossref_primary_10_3390_healthcare13172201 crossref_primary_10_1210_endrev_bnab028 crossref_primary_10_1080_13685538_2024_2419853 crossref_primary_10_1016_j_cca_2022_04_995 crossref_primary_10_1038_s41467_022_29235_2 crossref_primary_10_2217_bmm_2020_0495 crossref_primary_10_1007_s11701_025_02395_1 crossref_primary_10_1016_j_ejso_2024_108319 crossref_primary_10_1002_pon_5749 crossref_primary_10_1016_j_acuroe_2020_05_010 crossref_primary_10_1002_jcla_24098 crossref_primary_10_1007_s00259_021_05594_8 crossref_primary_10_2147_DDDT_S291369 crossref_primary_10_1111_jep_13791 crossref_primary_10_1038_s41598_025_98102_z crossref_primary_10_3390_cells13231958 crossref_primary_10_1007_s12032_020_01417_2 crossref_primary_10_1016_j_euo_2023_12_006 crossref_primary_10_1002_ctm2_1678 crossref_primary_10_1016_j_urolonc_2024_10_018 crossref_primary_10_1007_s11701_024_02123_1 crossref_primary_10_1186_s40359_023_01159_6 crossref_primary_10_1080_14737140_2025_2483853 crossref_primary_10_1177_03000605231204429 crossref_primary_10_2147_CMAR_S257701 crossref_primary_10_3390_jpm13030431 crossref_primary_10_1007_s12094_024_03682_3 crossref_primary_10_1038_s41443_023_00782_6 crossref_primary_10_1186_s12893_024_02522_z crossref_primary_10_1002_adma_202415322 crossref_primary_10_1002_cnr2_1817 crossref_primary_10_1002_jbio_70046 crossref_primary_10_1016_j_jddst_2024_105345 crossref_primary_10_1016_j_lfs_2023_122270 crossref_primary_10_3390_medicines8060028 crossref_primary_10_1096_fj_202501885R crossref_primary_10_1007_s00261_023_04021_w crossref_primary_10_1186_s12880_023_01002_9 crossref_primary_10_1007_s00259_025_07404_x crossref_primary_10_3390_jpm11070605 crossref_primary_10_7717_peerj_cs_1767 crossref_primary_10_1007_s40610_022_00147_w crossref_primary_10_1007_s11010_025_05222_1 crossref_primary_10_1007_s40141_021_00307_6 crossref_primary_10_1002_pros_24360 crossref_primary_10_1016_j_seminoncol_2025_152391 crossref_primary_10_1002_pros_24364 crossref_primary_10_3322_caac_21660 crossref_primary_10_3389_fpubh_2025_1553747 crossref_primary_10_1016_j_urolonc_2021_07_016 crossref_primary_10_1177_15330338231166766 crossref_primary_10_3390_diagnostics14111184 crossref_primary_10_1016_j_euf_2022_09_002 crossref_primary_10_1007_s11307_023_01891_w crossref_primary_10_1002_ctm2_1411 crossref_primary_10_1016_j_euros_2024_02_004 crossref_primary_10_1111_bju_15891 crossref_primary_10_3390_cells9081764 crossref_primary_10_1007_s13139_025_00946_w crossref_primary_10_47413_wggk3t17 crossref_primary_10_4274_jus_galenos_2022_2022_0084 crossref_primary_10_1016_j_eucr_2025_103172 crossref_primary_10_1177_03946320231158025 crossref_primary_10_1186_s12957_025_03937_5 crossref_primary_10_1016_j_heliyon_2023_e21174 crossref_primary_10_3389_fpubh_2025_1595159 crossref_primary_10_1016_j_rx_2022_12_005 crossref_primary_10_3390_chemosensors12110228 crossref_primary_10_1158_1541_7786_MCR_21_0806 crossref_primary_10_1016_j_gene_2021_145953 crossref_primary_10_1038_s41585_021_00445_5 crossref_primary_10_3390_ijerph182413269 crossref_primary_10_1002_fsn3_3869 crossref_primary_10_33719_nju1557986 crossref_primary_10_1002_cam4_6728 crossref_primary_10_1038_s41598_024_78085_z crossref_primary_10_3389_fonc_2023_1094943 crossref_primary_10_1007_s12079_022_00671_5 crossref_primary_10_1097_MOU_0000000000001268 crossref_primary_10_3390_app13179871 crossref_primary_10_1007_s00120_024_02275_w crossref_primary_10_3390_biomedicines13051051 crossref_primary_10_1155_2021_9483433 crossref_primary_10_1159_000510319 crossref_primary_10_3762_bjnano_13_47 crossref_primary_10_1007_s10552_021_01480_8 crossref_primary_10_1097_MD_0000000000026985 crossref_primary_10_1007_s12094_025_04016_7 crossref_primary_10_1186_s12885_025_14230_9 crossref_primary_10_1186_s12889_023_17440_7 crossref_primary_10_3390_cancers16152620 crossref_primary_10_3390_cancers16081510 crossref_primary_10_1001_jamanetworkopen_2021_19568 crossref_primary_10_1002_jbio_202400278 crossref_primary_10_1002_mc_23609 crossref_primary_10_3390_cancers15235612 crossref_primary_10_1186_s43046_025_00265_3 crossref_primary_10_1016_j_clgc_2021_03_021 crossref_primary_10_1016_j_snb_2022_131413 crossref_primary_10_3389_fendo_2022_1012005 crossref_primary_10_3390_ijms25116032 crossref_primary_10_1007_s13258_022_01316_y crossref_primary_10_3389_fmolb_2023_980433 crossref_primary_10_1016_j_canep_2024_102704 crossref_primary_10_3390_jcm14124377 crossref_primary_10_3390_ijms241713603 crossref_primary_10_1080_01913123_2024_2379300 crossref_primary_10_1186_s13690_023_01087_2 crossref_primary_10_1097_CEJ_0000000000000890 crossref_primary_10_1007_s00432_023_05582_5 crossref_primary_10_1259_bjr_20210458 crossref_primary_10_1186_s12301_024_00470_x crossref_primary_10_1186_s40164_023_00444_9 crossref_primary_10_1016_j_heliyon_2024_e30766 crossref_primary_10_3389_fphar_2021_732266 crossref_primary_10_3390_jpm13060938 crossref_primary_10_1038_s41598_022_23752_2 crossref_primary_10_3390_jcm14103444 crossref_primary_10_1007_s43440_021_00349_6 crossref_primary_10_3390_cancers15184466 crossref_primary_10_1007_s00120_025_02592_8 crossref_primary_10_3390_jpm11111088 crossref_primary_10_1186_s12894_023_01177_x crossref_primary_10_1186_s12894_025_01848_x crossref_primary_10_1016_j_urolonc_2020_08_010 crossref_primary_10_1007_s00345_020_03530_3 crossref_primary_10_1007_s00604_023_05750_x crossref_primary_10_1159_000530435 crossref_primary_10_3390_proteomes11010002 crossref_primary_10_1016_j_urology_2023_02_013 crossref_primary_10_4236_health_2023_1510074 crossref_primary_10_1097_CEJ_0000000000000639 crossref_primary_10_1007_s00259_023_06326_w crossref_primary_10_1093_carcin_bgab015 crossref_primary_10_1186_s12885_023_10732_6 crossref_primary_10_1097_CM9_0000000000003442 crossref_primary_10_3322_caac_21834 crossref_primary_10_1016_j_heliyon_2023_e22604 crossref_primary_10_1177_07482337221129162 crossref_primary_10_1155_2023_8295113 crossref_primary_10_2147_OTT_S264347 crossref_primary_10_1007_s11033_025_10924_2 crossref_primary_10_1016_j_cct_2024_107563 crossref_primary_10_3390_jcm13020423 crossref_primary_10_3390_nu14061225 crossref_primary_10_1002_slct_202203768 crossref_primary_10_1007_s00120_023_02173_7 crossref_primary_10_1007_s11356_022_24266_0 crossref_primary_10_1159_000529873 crossref_primary_10_1016_j_jvir_2025_05_024 crossref_primary_10_1016_j_tranon_2022_101495 crossref_primary_10_1007_s00520_021_06720_w crossref_primary_10_3390_molecules26082232 crossref_primary_10_1016_j_pdpdt_2023_103900 crossref_primary_10_1097_RCT_0000000000001514 crossref_primary_10_1016_j_ucl_2020_07_010 crossref_primary_10_1016_j_heliyon_2024_e33834 crossref_primary_10_1002_aidi_202500077 crossref_primary_10_1002_pros_24271 crossref_primary_10_1186_s12894_025_01717_7 crossref_primary_10_3390_bios11110437 crossref_primary_10_1002_pros_24258 crossref_primary_10_1016_j_urolonc_2023_07_009 crossref_primary_10_1186_s13102_023_00756_7 crossref_primary_10_1016_j_snb_2023_134040 crossref_primary_10_1158_1078_0432_CCR_22_0851 crossref_primary_10_37689_acta_ape_2020AO02375 crossref_primary_10_3389_fphar_2022_963317 crossref_primary_10_56294_dm202275 crossref_primary_10_1007_s00520_021_06753_1 crossref_primary_10_3390_jcm10050999 crossref_primary_10_1038_s41443_025_01047_0 crossref_primary_10_3390_cancers17030372 crossref_primary_10_1186_s12885_022_09266_0 crossref_primary_10_1002_pmic_202100147 crossref_primary_10_7717_peerj_19065 crossref_primary_10_1038_s41746_024_01167_9 crossref_primary_10_2478_raon_2024_0060 crossref_primary_10_1016_j_euros_2024_10_023 crossref_primary_10_2217_fon_2023_0227 crossref_primary_10_1016_j_critrevonc_2025_104819 crossref_primary_10_1016_j_urology_2025_07_038 crossref_primary_10_1186_s12301_024_00419_0 crossref_primary_10_1002_jbio_202200121 crossref_primary_10_1200_EDBK_390166 crossref_primary_10_1016_j_eururo_2022_03_007 crossref_primary_10_3390_siuj6030044 crossref_primary_10_1186_s12885_022_09331_8 crossref_primary_10_1007_s11701_024_01964_0 crossref_primary_10_5694_mja2_50455 crossref_primary_10_1002_pros_24293 crossref_primary_10_1016_j_biomaterials_2024_122469 crossref_primary_10_3390_jpm14101058 crossref_primary_10_1016_j_euros_2023_07_007 crossref_primary_10_1007_s10334_025_01264_0 crossref_primary_10_1002_tox_23874 crossref_primary_10_1001_jamanetworkopen_2022_31024 crossref_primary_10_3389_fonc_2024_1432857 crossref_primary_10_1007_s00259_024_06714_w crossref_primary_10_3390_jcm11123451 crossref_primary_10_3389_fonc_2022_865317 crossref_primary_10_3390_genes16020148 crossref_primary_10_1021_acs_jmedchem_5c00130 crossref_primary_10_1136_jitc_2020_000928 crossref_primary_10_1002_pros_24040 crossref_primary_10_3390_uro3010009 crossref_primary_10_1002_pros_24287 crossref_primary_10_3389_fonc_2021_695251 crossref_primary_10_1007_s10552_025_02044_w crossref_primary_10_1097_MS9_0000000000001448 crossref_primary_10_1016_j_clgc_2024_102155 crossref_primary_10_3390_jcm13102774 crossref_primary_10_1038_s41598_024_82555_9 crossref_primary_10_2174_0115701808241219230923154750 crossref_primary_10_3390_cancers15225485 crossref_primary_10_3390_ijms25126646 crossref_primary_10_1097_CCO_0000000000001025 crossref_primary_10_1186_s13020_025_01086_1 crossref_primary_10_1016_j_jgo_2024_101792 crossref_primary_10_1177_15579883211026515 crossref_primary_10_1016_j_urolonc_2023_04_009 crossref_primary_10_1007_s13139_023_00832_3 crossref_primary_10_1016_j_fct_2024_114548 crossref_primary_10_3390_cancers15030945 crossref_primary_10_3390_jcm9123826 crossref_primary_10_1080_08941939_2022_2062495 crossref_primary_10_7554_eLife_81258 crossref_primary_10_1007_s00259_022_05721_z crossref_primary_10_1002_ijc_34028 crossref_primary_10_1016_j_urology_2022_09_014 crossref_primary_10_1007_s40336_024_00666_9 crossref_primary_10_3389_fpubh_2023_1080800 crossref_primary_10_1177_20503121211032812 crossref_primary_10_1186_s41043_024_00641_0 crossref_primary_10_2478_sjecr_2023_0011 crossref_primary_10_1016_j_bmc_2021_116583 crossref_primary_10_1016_j_pathol_2022_10_012 crossref_primary_10_3389_fonc_2024_1451941 crossref_primary_10_1155_2022_5794055 crossref_primary_10_1007_s00261_023_03989_9 crossref_primary_10_1007_s12672_025_02877_6 crossref_primary_10_1016_j_tranon_2022_101438 crossref_primary_10_3390_biom12020193 crossref_primary_10_1080_14737140_2024_2445152 crossref_primary_10_1136_bmjopen_2024_096431 crossref_primary_10_1016_j_soncn_2020_151048 crossref_primary_10_1002_jbio_202200334 crossref_primary_10_3892_etm_2022_11528 crossref_primary_10_1186_s40959_024_00278_2 crossref_primary_10_1016_j_soncn_2020_151040 crossref_primary_10_1186_s13046_022_02243_2 crossref_primary_10_3390_nu14193886 crossref_primary_10_1002_jmri_29661 crossref_primary_10_1016_j_urolonc_2025_08_018 crossref_primary_10_3390_cancers15030979 crossref_primary_10_1097_CEJ_0000000000000806 crossref_primary_10_1007_s12672_024_01387_1 crossref_primary_10_1038_s41388_023_02807_2 crossref_primary_10_3390_cancers15123103 crossref_primary_10_1016_j_prp_2025_155916 crossref_primary_10_1007_s12094_022_02982_w crossref_primary_10_1111_iju_15641 crossref_primary_10_1016_j_mednuc_2022_12_001 crossref_primary_10_3389_fphar_2020_00719 crossref_primary_10_1186_s40779_025_00621_3 crossref_primary_10_1097_CEJ_0000000000000852 crossref_primary_10_3389_fonc_2024_1354235 crossref_primary_10_1002_gcc_23190 crossref_primary_10_1080_19390211_2023_2284985 crossref_primary_10_1016_j_clgc_2022_09_006 crossref_primary_10_3389_fcell_2021_679527 crossref_primary_10_1007_s12094_022_02916_6 crossref_primary_10_1080_14737159_2021_1935881 crossref_primary_10_1038_s41598_023_31021_z crossref_primary_10_1007_s11934_024_01249_x crossref_primary_10_4103_UCCI_UCCI_5_24 crossref_primary_10_1007_s11136_021_02954_7 crossref_primary_10_3390_jpm15080367 crossref_primary_10_1080_07853890_2021_1991591 crossref_primary_10_1080_14737140_2025_2555466 crossref_primary_10_1177_15579883251319125 crossref_primary_10_3390_antiox13010073 crossref_primary_10_3390_life14070868 crossref_primary_10_1016_j_suronc_2024_102148 crossref_primary_10_1038_s43018_024_00820_2 crossref_primary_10_3390_cancers16203453 crossref_primary_10_3389_fcell_2022_851359 crossref_primary_10_1111_ecc_13493 crossref_primary_10_3892_ol_2024_14585 crossref_primary_10_1002_tre_833 crossref_primary_10_1038_s41419_024_06734_2 crossref_primary_10_1007_s00345_023_04406_y crossref_primary_10_2196_47161 crossref_primary_10_3892_ijo_2025_5785 crossref_primary_10_1155_2023_9736073 crossref_primary_10_1007_s11307_025_02020_5 crossref_primary_10_1016_j_prnil_2024_03_003 crossref_primary_10_1016_j_euo_2021_05_005 crossref_primary_10_1007_s00120_021_01554_0 crossref_primary_10_1038_s41598_021_99586_1 crossref_primary_10_3390_jpm15080360 crossref_primary_10_1080_01913123_2022_2115596 crossref_primary_10_1016_j_ejmech_2023_115844 crossref_primary_10_7717_peerj_16614 crossref_primary_10_1080_13557858_2023_2174253 crossref_primary_10_1080_13685538_2022_2091130 crossref_primary_10_1097_MD_0000000000039119 crossref_primary_10_3389_fmolb_2022_803474 crossref_primary_10_1007_s44258_023_00002_2 crossref_primary_10_1186_s12894_022_01141_1 crossref_primary_10_1038_s41419_022_05086_z crossref_primary_10_1038_s41598_022_13332_9 crossref_primary_10_3390_ijms23084191 |
| Cites_doi | 10.1136/bmj.k3581 10.7326/0003-4819-157-2-201207170-00459 10.1016/j.eururo.2012.02.054 10.1002/ijc.29670 10.1016/j.prnil.2016.09.002 10.5489/cuaj.4486 10.1016/j.eururo.2013.06.051 10.1002/ijc.25517 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z 10.1016/j.orcp.2013.06.002 10.1093/jnci/91.12.1025 10.1111/bju.13602 10.1016/S1470-2045(14)70211-6 10.1001/jama.2015.14905 10.1001/jamainternmed.2017.0340 10.1016/j.eururo.2018.08.026 10.1056/NEJMoa0810084 10.1001/jama.2018.0154 10.1002/cncr.31549 10.1002/mnfr.200700511 10.1002/cncr.31337 10.1093/aje/kwv089 10.1186/s12885-018-4625-x 10.1093/oxfordjournals.aje.a009698 10.7326/0003-4819-149-3-200808050-00008 10.1093/jnci/dji065 10.1016/j.eururo.2010.03.033 10.1111/bju.12556 10.1111/j.1442-2042.2010.02613.x 10.1016/S0140-6736(15)60171-4 10.1097/MOU.0000000000000383 10.1001/jama.2018.3710 10.1590/s1677-5538.ibju.2015.0690 10.4103/1008-682X.143756 |
| ContentType | Journal Article |
| Copyright | 2019 European Association of Urology Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2019 European Association of Urology – notice: Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.eururo.2019.08.005 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-7560 |
| EndPage | 52 |
| ExternalDocumentID | 31493960 10_1016_j_eururo_2019_08_005 S0302283819306190 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 0~B 1B1 1P~ 1~. 1~5 29G 30W 34G 39C 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 8UI AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYIC AAYWO ABBQC ABBTS ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWCG ABWVN ABXDB ACDAQ ACIEU ACLOT ACQXL ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AEYAO AFJKZ AFPUW AFRHN AFSIO AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CAG COF CS3 CYUIP DU5 E0A EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FB. FDB FEDTE FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O1H O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 RKO ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UDS UJ6 UV1 X7M Z5R ZGI ZXP ~G- ~HD AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW AZPMC LCYCR RIG ZA5 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c481t-5efe96d950f2495c58c9b314c4802bde39c416553832b165bfe5004d1a55039d3 |
| ISICitedReferencesCount | 978 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000502251900020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0302-2838 1873-7560 |
| IngestDate | Thu Oct 02 11:30:37 EDT 2025 Mon Jul 21 05:42:28 EDT 2025 Tue Nov 18 21:32:26 EST 2025 Sat Nov 29 07:23:17 EST 2025 Fri Feb 23 02:50:45 EST 2024 Tue Oct 14 19:39:08 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Prostate-specific antigen testing Prostate cancer Global patterns |
| Language | English |
| License | Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c481t-5efe96d950f2495c58c9b314c4802bde39c416553832b165bfe5004d1a55039d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-7851-0233 0000-0003-0996-0350 |
| PMID | 31493960 |
| PQID | 2287514350 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_2287514350 pubmed_primary_31493960 crossref_primary_10_1016_j_eururo_2019_08_005 crossref_citationtrail_10_1016_j_eururo_2019_08_005 elsevier_sciencedirect_doi_10_1016_j_eururo_2019_08_005 elsevier_clinicalkey_doi_10_1016_j_eururo_2019_08_005 |
| PublicationCentury | 2000 |
| PublicationDate | January 2020 2020-01-00 20200101 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – month: 01 year: 2020 text: January 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | European urology |
| PublicationTitleAlternate | Eur Urol |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Kim, Fay, Feuer, Midthune (bib0170) 2000; 19 Engholm G, Ferlay J, Christensen N, et al. Cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 8.1 (28.06.2018). Association of the Nordic Cancer Registries. Danish Cancer Society. Martin, Donovan, Turner (bib0215) 2018; 319 Parkin, Ferlay, Curado (bib0160) 2010; 127 National Cancer Institute (bib0150) 2018 Eapen, Herlemann, Washington, Cooperberg (bib0045) 2017; 27 Fowke, Mclerran, Gupta (bib0250) 2015; 182 Schroder, Hugosson, Roobol (bib0195) 2009; 360 Bray, Ferlay, Laversanne (bib0140) 2015; 137 Murphy, Ahlering, Catalona (bib0190) 2014; 113 Baade, Youlden, Krnjacki (bib0235) 2009; 53 Cabarkapa, Perera, McGrath, Lawrentschuk (bib0115) 2016; 4 Kitagawa, Nakimi (bib0085) 2015; 17 Cuzick, Thorat, Andriole (bib0210) 2014; 15 Schroder, Roobol (bib0205) 2010; 58 Ziegler-Johnson, Spangler, Jalloh, Gueye, Rennert, Rebbeck (bib0230) 2008; 15 Zargar, van den Bergh, Moon, Lawrentschuk, Costello, Murphy (bib0185) 2017; 119 Platz, Giovannucci (bib0010) 2006 Hayes, Ziegler, Gridley (bib0015) 1999; 8 International Agency for Research on Cancer. Global initiative for cancer registry development. American Urological Association (bib0070) 2009 United States Preventive Services Task Force (bib0030) 2008; 149 Jemal, Fedewa, Ma (bib0040) 2015; 314 Tonon, Fromont, Boyault (bib0020) 2018; 75 Center, Jemal, Lortet-Tieulent (bib0135) 2012; 61 Tourinho-Barbosa, Pompeo, Glina (bib0110) 2016; 42 United States Preventive Services Task Force (bib0075) 2018; 319 Segone, Haffejee, Wentzel (bib0100) 2013 Etzioni, Cha, Feuer, Davidov (bib0130) 1998; 148 Warner, Lee, Badal (bib0225) 2018; 18 Kearns, Holt, Wright, Lin, Lange, Gore (bib0050) 2018; 124 National Cancer Institute (bib0165) 2018 Ferlay, Ervik, Lam (bib0005) 2018 Feuer, Merrill, Hankey (bib0245) 1999; 91 United States Preventive Services Task Force (bib0035) 2012; 157 Wolf, Wender, Etzioni (bib0065) 2010; 60 Doll, Payne, Waterhouse (bib0180) 1966; Vol. 1 Andriole, Levin, Crawford (bib0200) 2005; 97 Ferlay, Colombet, Bray (bib0120) 2018 2019. Haque, Van Den Eeden, Wallner (bib0220) 2014; 8 Association of European Cancer Leagues (bib0105) 2018 Tikkinen, Dahm, Lytvyn (bib0025) 2018; 362 Negoita, Feuer, Mariotto (bib0060) 2018; 124 Heindenreich, Abrahamsson, Artibani (bib0095) 2013; 64 Segi (bib0175) 1960 Fedewa, Ward, Brawley, Jemal (bib0055) 2017; 177 World Health Organization, Department of Information, Evidence and Research, mortality database. Mikkelsen, Phillips, AbouZahr (bib0145) 2015; 386 Goldenberg, Skeldon, Nayan (bib0080) 2017; 11 The Japanese Urological Association (bib0090) 2010; 17 Warner (10.1016/j.eururo.2019.08.005_bib0225) 2018; 18 10.1016/j.eururo.2019.08.005_bib0155 Schroder (10.1016/j.eururo.2019.08.005_bib0195) 2009; 360 Ferlay (10.1016/j.eururo.2019.08.005_bib0005) American Urological Association (10.1016/j.eururo.2019.08.005_bib0070) 2009 Kitagawa (10.1016/j.eururo.2019.08.005_bib0085) 2015; 17 Andriole (10.1016/j.eururo.2019.08.005_bib0200) 2005; 97 Cuzick (10.1016/j.eururo.2019.08.005_bib0210) 2014; 15 The Japanese Urological Association (10.1016/j.eururo.2019.08.005_bib0090) 2010; 17 Cabarkapa (10.1016/j.eururo.2019.08.005_bib0115) 2016; 4 10.1016/j.eururo.2019.08.005_bib0240 Segone (10.1016/j.eururo.2019.08.005_bib0100) 10.1016/j.eururo.2019.08.005_bib0125 Etzioni (10.1016/j.eururo.2019.08.005_bib0130) 1998; 148 Martin (10.1016/j.eururo.2019.08.005_bib0215) 2018; 319 Bray (10.1016/j.eururo.2019.08.005_bib0140) 2015; 137 Fowke (10.1016/j.eururo.2019.08.005_bib0250) 2015; 182 Wolf (10.1016/j.eururo.2019.08.005_bib0065) 2010; 60 Ziegler-Johnson (10.1016/j.eururo.2019.08.005_bib0230) 2008; 15 National Cancer Institute (10.1016/j.eururo.2019.08.005_bib0165) 2018 Tikkinen (10.1016/j.eururo.2019.08.005_bib0025) 2018; 362 Schroder (10.1016/j.eururo.2019.08.005_bib0205) 2010; 58 United States Preventive Services Task Force (10.1016/j.eururo.2019.08.005_bib0030) 2008; 149 National Cancer Institute (10.1016/j.eururo.2019.08.005_bib0150) 2018 Baade (10.1016/j.eururo.2019.08.005_bib0235) 2009; 53 Association of European Cancer Leagues (10.1016/j.eururo.2019.08.005_bib0105) 2018 Ferlay (10.1016/j.eururo.2019.08.005_bib0120) Negoita (10.1016/j.eururo.2019.08.005_bib0060) 2018; 124 Fedewa (10.1016/j.eururo.2019.08.005_bib0055) 2017; 177 Haque (10.1016/j.eururo.2019.08.005_bib0220) 2014; 8 Murphy (10.1016/j.eururo.2019.08.005_bib0190) 2014; 113 Goldenberg (10.1016/j.eururo.2019.08.005_bib0080) 2017; 11 Feuer (10.1016/j.eururo.2019.08.005_bib0245) 1999; 91 Platz (10.1016/j.eururo.2019.08.005_bib0010) 2006 Segi (10.1016/j.eururo.2019.08.005_bib0175) 1960 Kearns (10.1016/j.eururo.2019.08.005_bib0050) 2018; 124 Parkin (10.1016/j.eururo.2019.08.005_bib0160) 2010; 127 Zargar (10.1016/j.eururo.2019.08.005_bib0185) 2017; 119 United States Preventive Services Task Force (10.1016/j.eururo.2019.08.005_bib0035) 2012; 157 Jemal (10.1016/j.eururo.2019.08.005_bib0040) 2015; 314 United States Preventive Services Task Force (10.1016/j.eururo.2019.08.005_bib0075) 2018; 319 Hayes (10.1016/j.eururo.2019.08.005_bib0015) 1999; 8 Kim (10.1016/j.eururo.2019.08.005_bib0170) 2000; 19 Center (10.1016/j.eururo.2019.08.005_bib0135) 2012; 61 Eapen (10.1016/j.eururo.2019.08.005_bib0045) 2017; 27 Doll (10.1016/j.eururo.2019.08.005_bib0180) 1966; Vol. 1 Tonon (10.1016/j.eururo.2019.08.005_bib0020) 2018; 75 Mikkelsen (10.1016/j.eururo.2019.08.005_bib0145) 2015; 386 Heindenreich (10.1016/j.eururo.2019.08.005_bib0095) 2013; 64 Tourinho-Barbosa (10.1016/j.eururo.2019.08.005_bib0110) 2016; 42 31843337 - Eur Urol. 2020 May;77(5):e132. doi: 10.1016/j.eururo.2019.11.030. 31627967 - Eur Urol. 2020 Jan;77(1):53-54. doi: 10.1016/j.eururo.2019.09.018. |
| References_xml | – volume: 119 start-page: 110 year: 2017 end-page: 115 ident: bib0185 article-title: The impact of the United States Preventive Services Task Force (USPSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia publication-title: BJU Int – volume: 75 start-page: 11 year: 2018 end-page: 15 ident: bib0020 article-title: Mutational profile of aggressive, localised prostate cancer from African Caribbean men versus European ancestry men publication-title: Eur Urol – start-page: 1128 year: 2006 end-page: 1150 ident: bib0010 article-title: Prostate cancer. In: Cancer epidemiology and prevention – volume: 137 start-page: 2060 year: 2015 end-page: 2071 ident: bib0140 article-title: Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration publication-title: Int J Cancer – year: 2018 ident: bib0150 article-title: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Research Data Nov 2017 Sub (1973-2015) <Katrina/Rita Population Adjustment> – volume: 8 start-page: 25 year: 1999 end-page: 34 ident: bib0015 article-title: Dietary factors and risks for prostate cancer among blacks and whites in the United States publication-title: Cancer Epidemiol Biomarkers Prev – volume: 18 start-page: 712 year: 2018 end-page: 724 ident: bib0225 article-title: Cancer incidence and mortality rates and trends in Trinidad and Tobago publication-title: BMC Cancer – reference: Engholm G, Ferlay J, Christensen N, et al. Cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 8.1 (28.06.2018). Association of the Nordic Cancer Registries. Danish Cancer Society. – volume: 148 start-page: 775 year: 1998 end-page: 785 ident: bib0130 article-title: Asymptomatic incidence and duration of prostate cancer publication-title: Am J Epidemiol – volume: 61 start-page: 1079 year: 2012 end-page: 1092 ident: bib0135 article-title: International variation in prostate cancer incidence and mortality rates publication-title: Eur Urol – volume: 127 start-page: 2918 year: 2010 end-page: 2927 ident: bib0160 article-title: Fifty years of cancer incidence: CI5 I-IX publication-title: Int J Cancer – volume: 8 start-page: e374 year: 2014 end-page: e381 ident: bib0220 article-title: Association of Body Mass Index and Prostate Cancer Mortality publication-title: Obes Res Clin Pract – volume: 15 start-page: e484 year: 2014 end-page: 92 ident: bib0210 article-title: Prevention and early detection of prostate cancer publication-title: Lancet Oncol – volume: 42 start-page: 1081 year: 2016 end-page: 1090 ident: bib0110 article-title: Prostate cancer in Brazil and Latin America: epidemiology and screening publication-title: Int Braz J Urol – volume: 4 start-page: 125 year: 2016 end-page: 129 ident: bib0115 article-title: Prostate cancer screening with prostate-specific antigen: a guide to the guidelines publication-title: Prostate Int – volume: 15 start-page: 3872 year: 2008 end-page: 3882 ident: bib0230 article-title: Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes publication-title: Can J Urol – volume: 17 start-page: 475 year: 2015 end-page: 480 ident: bib0085 article-title: Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia publication-title: Asian J Androl – volume: 53 start-page: 171 year: 2009 end-page: 184 ident: bib0235 article-title: International epidemiology of prostate cancer: geographical distribution and secular trends publication-title: Mol Nutr Food Res – volume: 64 start-page: 347 year: 2013 end-page: 354 ident: bib0095 article-title: Early detection of prostate cancer: European Association of Urology recommendation publication-title: Eur Urol – year: 1960 ident: bib0175 article-title: Cancer mortality for selected sites in 24 countries (1950–57) – volume: 177 start-page: 1040 year: 2017 end-page: 1042 ident: bib0055 article-title: Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States publication-title: JAMA Intern Med – year: 2018 ident: bib0105 article-title: The European code against cancer – volume: 319 start-page: 1901 year: 2018 end-page: 1913 ident: bib0075 article-title: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement publication-title: JAMA – volume: 362 start-page: k3581 year: 2018 ident: bib0025 article-title: Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline publication-title: BMJ – volume: 182 start-page: 381 year: 2015 end-page: 389 ident: bib0250 article-title: Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium publication-title: Am J Epidemiol – volume: 58 start-page: 46 year: 2010 end-page: 52 ident: bib0205 article-title: ERSPC and PLCO prostate cancer screening studies: what are the differences? publication-title: Eur Urol – volume: 314 start-page: 2054 year: 2015 end-page: 2061 ident: bib0040 article-title: Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations publication-title: JAMA – volume: 149 start-page: 185 year: 2008 end-page: 191 ident: bib0030 article-title: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement publication-title: Ann Intern Med – volume: 27 start-page: 205 year: 2017 end-page: 209 ident: bib0045 article-title: Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging publication-title: Curr Opin Urol – volume: 97 start-page: 433 year: 2005 end-page: 438 ident: bib0200 article-title: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial publication-title: J Natl Cancer Inst – volume: 360 start-page: 1320 year: 2009 end-page: 1328 ident: bib0195 article-title: Screening and prostate-cancer mortality in a randomized European study publication-title: N Engl J Med – year: 2009 ident: bib0070 article-title: Prostate-specific antigen best practice statement – volume: 157 start-page: 120 year: 2012 end-page: 134 ident: bib0035 article-title: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement publication-title: Ann Intern Med – volume: 124 start-page: 2733 year: 2018 end-page: 2739 ident: bib0050 article-title: PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening publication-title: Cancer – volume: 386 start-page: 1395 year: 2015 end-page: 1406 ident: bib0145 article-title: A global assessment of civil registration and vital statistics systems: monitoring data quality and progress publication-title: Lancet – volume: 19 start-page: 335 year: 2000 end-page: 351 ident: bib0170 article-title: Permutation tests for joinpoint regression with applications to cancer rates publication-title: Stat Med – year: 2013 ident: bib0100 article-title: Prostate cancer diagnostic and treatment guidelines: the Prostate Cancer Foundation of South Africa – volume: 113 start-page: 186 year: 2014 end-page: 188 ident: bib0190 article-title: The Melbourne Consensus Statement on the early detection of prostate cancer publication-title: BJU Int – reference: International Agency for Research on Cancer. Global initiative for cancer registry development. – year: 2018 ident: bib0005 article-title: Global cancer observatory: cancer today – year: 2018 ident: bib0165 article-title: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality—All COD, Aggregated Total U.S (1969–2016)<Katrina/Rita Population Adjustment>. – volume: 319 start-page: 883 year: 2018 end-page: 895 ident: bib0215 article-title: Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial publication-title: JAMA – volume: Vol. 1 year: 1966 ident: bib0180 article-title: Cancer incidence in five continents publication-title: Union Internationale Contre le Cancer – volume: 124 start-page: 2801 year: 2018 end-page: 2814 ident: bib0060 article-title: Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics publication-title: Cancer – reference: World Health Organization, Department of Information, Evidence and Research, mortality database. – volume: 60 start-page: 70 year: 2010 end-page: 98 ident: bib0065 article-title: American Cancer Society guideline for the early detection of prostate cancer: update 2010 publication-title: CA Cancer J Clin – volume: 17 start-page: 830 year: 2010 end-page: 838 ident: bib0090 article-title: Updated Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer in 2010 publication-title: Int J Urol – volume: 11 start-page: 396 year: 2017 end-page: 403 ident: bib0080 article-title: Prostate-specific antigen testing for prostate cancer screening: a national survey of Canadian primary care physicians’ opinions and practices publication-title: Can Urol Assoc J – year: 2018 ident: bib0120 article-title: Cancer incidence in five continents, CI5 – volume: 91 start-page: 1025 year: 1999 end-page: 1032 ident: bib0245 article-title: Cancer surveillance series: interpreting trends in prostate cancer—part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality publication-title: J Natl Cancer Inst – reference: . 2019. – year: 2009 ident: 10.1016/j.eururo.2019.08.005_bib0070 – year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0165 – volume: 362 start-page: k3581 year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0025 article-title: Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline publication-title: BMJ doi: 10.1136/bmj.k3581 – volume: 157 start-page: 120 year: 2012 ident: 10.1016/j.eururo.2019.08.005_bib0035 article-title: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement publication-title: Ann Intern Med doi: 10.7326/0003-4819-157-2-201207170-00459 – volume: Vol. 1 year: 1966 ident: 10.1016/j.eururo.2019.08.005_bib0180 article-title: Cancer incidence in five continents – volume: 61 start-page: 1079 year: 2012 ident: 10.1016/j.eururo.2019.08.005_bib0135 article-title: International variation in prostate cancer incidence and mortality rates publication-title: Eur Urol doi: 10.1016/j.eururo.2012.02.054 – volume: 137 start-page: 2060 year: 2015 ident: 10.1016/j.eururo.2019.08.005_bib0140 article-title: Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration publication-title: Int J Cancer doi: 10.1002/ijc.29670 – volume: 15 start-page: 3872 year: 2008 ident: 10.1016/j.eururo.2019.08.005_bib0230 article-title: Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes publication-title: Can J Urol – volume: 4 start-page: 125 year: 2016 ident: 10.1016/j.eururo.2019.08.005_bib0115 article-title: Prostate cancer screening with prostate-specific antigen: a guide to the guidelines publication-title: Prostate Int doi: 10.1016/j.prnil.2016.09.002 – volume: 11 start-page: 396 year: 2017 ident: 10.1016/j.eururo.2019.08.005_bib0080 article-title: Prostate-specific antigen testing for prostate cancer screening: a national survey of Canadian primary care physicians’ opinions and practices publication-title: Can Urol Assoc J doi: 10.5489/cuaj.4486 – volume: 64 start-page: 347 year: 2013 ident: 10.1016/j.eururo.2019.08.005_bib0095 article-title: Early detection of prostate cancer: European Association of Urology recommendation publication-title: Eur Urol doi: 10.1016/j.eururo.2013.06.051 – ident: 10.1016/j.eururo.2019.08.005_bib0120 – volume: 127 start-page: 2918 year: 2010 ident: 10.1016/j.eururo.2019.08.005_bib0160 article-title: Fifty years of cancer incidence: CI5 I-IX publication-title: Int J Cancer doi: 10.1002/ijc.25517 – volume: 19 start-page: 335 year: 2000 ident: 10.1016/j.eururo.2019.08.005_bib0170 article-title: Permutation tests for joinpoint regression with applications to cancer rates publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z – volume: 8 start-page: e374 issue: 4 year: 2014 ident: 10.1016/j.eururo.2019.08.005_bib0220 article-title: Association of Body Mass Index and Prostate Cancer Mortality publication-title: Obes Res Clin Pract doi: 10.1016/j.orcp.2013.06.002 – volume: 91 start-page: 1025 year: 1999 ident: 10.1016/j.eururo.2019.08.005_bib0245 article-title: Cancer surveillance series: interpreting trends in prostate cancer—part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality publication-title: J Natl Cancer Inst doi: 10.1093/jnci/91.12.1025 – volume: 119 start-page: 110 year: 2017 ident: 10.1016/j.eururo.2019.08.005_bib0185 article-title: The impact of the United States Preventive Services Task Force (USPSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia publication-title: BJU Int doi: 10.1111/bju.13602 – volume: 8 start-page: 25 year: 1999 ident: 10.1016/j.eururo.2019.08.005_bib0015 article-title: Dietary factors and risks for prostate cancer among blacks and whites in the United States publication-title: Cancer Epidemiol Biomarkers Prev – volume: 15 start-page: e484 year: 2014 ident: 10.1016/j.eururo.2019.08.005_bib0210 article-title: Prevention and early detection of prostate cancer publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70211-6 – volume: 314 start-page: 2054 year: 2015 ident: 10.1016/j.eururo.2019.08.005_bib0040 article-title: Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations publication-title: JAMA doi: 10.1001/jama.2015.14905 – volume: 177 start-page: 1040 year: 2017 ident: 10.1016/j.eururo.2019.08.005_bib0055 article-title: Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2017.0340 – volume: 75 start-page: 11 year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0020 article-title: Mutational profile of aggressive, localised prostate cancer from African Caribbean men versus European ancestry men publication-title: Eur Urol doi: 10.1016/j.eururo.2018.08.026 – volume: 360 start-page: 1320 year: 2009 ident: 10.1016/j.eururo.2019.08.005_bib0195 article-title: Screening and prostate-cancer mortality in a randomized European study publication-title: N Engl J Med doi: 10.1056/NEJMoa0810084 – ident: 10.1016/j.eururo.2019.08.005_bib0125 – volume: 319 start-page: 883 year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0215 article-title: Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2018.0154 – year: 1960 ident: 10.1016/j.eururo.2019.08.005_bib0175 – volume: 124 start-page: 2801 year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0060 article-title: Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics publication-title: Cancer doi: 10.1002/cncr.31549 – volume: 53 start-page: 171 year: 2009 ident: 10.1016/j.eururo.2019.08.005_bib0235 article-title: International epidemiology of prostate cancer: geographical distribution and secular trends publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.200700511 – year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0150 – volume: 124 start-page: 2733 year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0050 article-title: PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening publication-title: Cancer doi: 10.1002/cncr.31337 – volume: 182 start-page: 381 issue: 5 year: 2015 ident: 10.1016/j.eururo.2019.08.005_bib0250 article-title: Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium publication-title: Am J Epidemiol doi: 10.1093/aje/kwv089 – volume: 18 start-page: 712 year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0225 article-title: Cancer incidence and mortality rates and trends in Trinidad and Tobago publication-title: BMC Cancer doi: 10.1186/s12885-018-4625-x – ident: 10.1016/j.eururo.2019.08.005_bib0005 – volume: 148 start-page: 775 year: 1998 ident: 10.1016/j.eururo.2019.08.005_bib0130 article-title: Asymptomatic incidence and duration of prostate cancer publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a009698 – volume: 60 start-page: 70 year: 2010 ident: 10.1016/j.eururo.2019.08.005_bib0065 article-title: American Cancer Society guideline for the early detection of prostate cancer: update 2010 publication-title: CA Cancer J Clin – volume: 149 start-page: 185 year: 2008 ident: 10.1016/j.eururo.2019.08.005_bib0030 article-title: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement publication-title: Ann Intern Med doi: 10.7326/0003-4819-149-3-200808050-00008 – volume: 97 start-page: 433 year: 2005 ident: 10.1016/j.eururo.2019.08.005_bib0200 article-title: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji065 – volume: 58 start-page: 46 year: 2010 ident: 10.1016/j.eururo.2019.08.005_bib0205 article-title: ERSPC and PLCO prostate cancer screening studies: what are the differences? publication-title: Eur Urol doi: 10.1016/j.eururo.2010.03.033 – volume: 113 start-page: 186 year: 2014 ident: 10.1016/j.eururo.2019.08.005_bib0190 article-title: The Melbourne Consensus Statement on the early detection of prostate cancer publication-title: BJU Int doi: 10.1111/bju.12556 – volume: 17 start-page: 830 year: 2010 ident: 10.1016/j.eururo.2019.08.005_bib0090 article-title: Updated Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer in 2010 publication-title: Int J Urol doi: 10.1111/j.1442-2042.2010.02613.x – volume: 386 start-page: 1395 year: 2015 ident: 10.1016/j.eururo.2019.08.005_bib0145 article-title: A global assessment of civil registration and vital statistics systems: monitoring data quality and progress publication-title: Lancet doi: 10.1016/S0140-6736(15)60171-4 – start-page: 1128 year: 2006 ident: 10.1016/j.eururo.2019.08.005_bib0010 – ident: 10.1016/j.eururo.2019.08.005_bib0155 – volume: 27 start-page: 205 year: 2017 ident: 10.1016/j.eururo.2019.08.005_bib0045 article-title: Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging publication-title: Curr Opin Urol doi: 10.1097/MOU.0000000000000383 – volume: 319 start-page: 1901 year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0075 article-title: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement publication-title: JAMA doi: 10.1001/jama.2018.3710 – year: 2018 ident: 10.1016/j.eururo.2019.08.005_bib0105 – ident: 10.1016/j.eururo.2019.08.005_bib0100 – volume: 42 start-page: 1081 year: 2016 ident: 10.1016/j.eururo.2019.08.005_bib0110 article-title: Prostate cancer in Brazil and Latin America: epidemiology and screening publication-title: Int Braz J Urol doi: 10.1590/s1677-5538.ibju.2015.0690 – ident: 10.1016/j.eururo.2019.08.005_bib0240 – volume: 17 start-page: 475 year: 2015 ident: 10.1016/j.eururo.2019.08.005_bib0085 article-title: Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia publication-title: Asian J Androl doi: 10.4103/1008-682X.143756 – reference: 31627967 - Eur Urol. 2020 Jan;77(1):53-54. doi: 10.1016/j.eururo.2019.09.018. – reference: 31843337 - Eur Urol. 2020 May;77(5):e132. doi: 10.1016/j.eururo.2019.11.030. |
| SSID | ssj0003593 |
| Score | 2.723711 |
| SecondaryResourceType | review_article |
| Snippet | Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 38 |
| SubjectTerms | Global Health Global patterns Humans Incidence Male Prostate cancer Prostate-specific antigen testing Prostatic Neoplasms - epidemiology Prostatic Neoplasms - mortality |
| Title | Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0302283819306190 https://dx.doi.org/10.1016/j.eururo.2019.08.005 https://www.ncbi.nlm.nih.gov/pubmed/31493960 https://www.proquest.com/docview/2287514350 |
| Volume | 77 |
| WOSCitedRecordID | wos000502251900020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-7560 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003593 issn: 0302-2838 databaseCode: AIEXJ dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9owELZoO017qfZ7dFvlSdNepkxJnOD4sUN069SxSqMSb1Z-OCoIJSxARf_73eXigNRWZQ97gShgSHxfzp_P5_sY--iaLMvzNHACkSZOkIoY_CAcGRUYT-CwE5PYhBwOo_FYXXQ6a7sX5nomiyJar9X8v5oazoGxcevsP5i7_VE4AcdgdHgFs8PrToYHIojr-1TMH0vwY8ivznq9wB0ewC0_99HUFfoGkhSlbIuaiNekHPnnnSF7eN-OwvdXs3mz4efmq1lebSScf5emmpbAhuOKEHe2iHGJo4XRIMdLuZqUK8rVRSHETVi1im-IVYONJ2Y7MuG7W5EJcqaRFI4MSS_gi7njXOOBGyGXbaSRO6XCL7e8PAUcplgaE-4b8_NUXYfVDTejml3JH_7Sp5fn53o0GI8-zf84qDeG6_KN-MoeO_BlqMAfHpycDcY_2lFcUMHm9nrttss6N_D2H99Ha-6bttT0ZfSUHTbzDn5CeHnGOqZ4zh7_bDIrXrBvBBtOsOEWNnxScAsbTrDhLWw4wIa3sOE1bF6yy9PBqP_daUQ2nDSIvKUTmtyoXqZCN0cZ8jSMUpUIL4BPXT_JjFApcPYQxkXhJ3CQ5CaEpy3zYpjbCpWJV2y_KAvzhnEF3CYTUqDMTuC7SRTAdMNILxYZEN2e7DJh-0inTQV6FEKZaZtqONXUsxp7VqM-qht2mdO2mlMFlge-H9ru13Z3MYyHGsDzQDvZtmvYJ7HKHVp-sFbW4JxxxS0uTLlaaN-PZD0jcbvsNZm_vQfoYyVUzz3aofVb9mTzgL1j-8tqZd6zR-n1crKojtmeHEfHDYD_ApVZulU |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+Global+Patterns+in+Prostate+Cancer+Incidence+and+Mortality+Rates&rft.jtitle=European+urology&rft.au=Culp%2C+MaryBeth+B&rft.au=Soerjomataram%2C+Isabelle&rft.au=Efstathiou%2C+Jason+A&rft.au=Bray%2C+Freddie&rft.date=2020-01-01&rft.issn=1873-7560&rft.eissn=1873-7560&rft.volume=77&rft.issue=1&rft.spage=38&rft_id=info:doi/10.1016%2Fj.eururo.2019.08.005&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0302-2838&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0302-2838&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0302-2838&client=summon |